Targeting the vaso-intestinal peptidergic system to decrease anxiety in Parkinson's disease
Adriane Guillaumin, Christelle Glangetas, Elodie Ladeveze, Sylvie Dumas, Sandra Dovero, Nathalie Biendon, Erwan Bézard, Francois Georges · FENS Forum 2024
The degeneration of dopamine neurons of the substantia nigra pars compacta is well-known in motor symptoms of Parkinson’s disease (PD). However, other dopaminergic populations degenerate and give rise to non-motor symptoms such as anxiety which has a high prevalence in PD patients and strongly affects quality of life. One of these structures, the dorsal raphe nucleus (DRN), has been identified as a potential structure involved in anxiety and depression in PD. Indeed, the dopaminergic neurons of the DRN degenerate in PD, and a part of them co-releases the vaso-intestinal peptide (VIP) onto two
ePoster · Neuroscience